Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2022-02-22 Regulatory Filings
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약해지
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from HLB Life Science regarding the termination of a single sales and supply contract. It details the contract cancellation, the financial impact, the reason for termination, and references previous related disclosures. Since this is a specific regulatory announcement regarding a material business event (contract termination) that does not fit into categories like M&A, financial reports, or director dealings, it is classified as a general Regulatory Filing (RNS).
2022-02-22 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from HLB Life Science regarding a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean market (DART system) for companies to announce preliminary financial results before the final audit is completed. Since it provides key financial highlights and performance metrics rather than a full annual report or a simple announcement of a report's availability, it falls under the 'Earnings Release' category. FY 2021
2022-02-14 Korean
기타시장안내(약명및영문명)(한글약명)
Regulatory Filings Classification · 95% confidence The document is a short notice regarding a change in the company's stock name (abbreviation) on the exchange. It does not contain financial statements, board changes, or other specific report types. As it is a miscellaneous regulatory announcement regarding market information, it falls under the RNS category.
2022-01-11 Korean
주요사항보고서(신주인수권부사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from HLB Life Science, specifically detailing the decision to issue Bonds with Warrants (BW). This type of filing is a formal regulatory disclosure regarding capital structure changes and financing activities. In the context of Korean corporate filings (DART system), this is classified as a capital/financing update.
2021-12-28 Korean
증권신고서(채무증권)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서(채무증권)' (Securities Registration Statement for Debt Securities) filed with the Financial Services Commission (FSC) in South Korea. It contains detailed information regarding the issuer (HLB Life Science), the nature of the securities, risk factors (business, industry, and company-specific risks), and financial disclosures. This is a formal regulatory filing required for public offerings of debt securities, which falls under the category of Regulatory Filings (RNS) as it is a formal legal disclosure document submitted to a regulatory body.
2021-12-28 Korean
타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 100% confidence The document is a regulatory filing from HLB Life Science regarding the acquisition of shares in another entity (Nomad Fund No. 2). It details the acquisition amount, purpose, and board approval. Since this is a specific corporate disclosure regarding an investment/acquisition of shares in another company, it falls under the category of general regulatory announcements (RNS) as it does not fit into specific categories like M&A (which usually implies a merger or takeover of a business entity) or share issuance/buybacks.
2021-12-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.